Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))

R. Campo; E. DeJesus; U. F. Bredeek; K. Henry; H. Khanlou; K. Logue

Article

Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45))

Clinical Infectious Diseases

DOI: 10.1093/cid/cit417

0Citations

2Readers

Get full text

Cite

CITATION STYLE

APA

Campo, R., DeJesus, E., Bredeek, U. F., Henry, K., Khanlou, H., & Logue, K. (2013, September 1). Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 (1637-45)). Clinical Infectious Diseases. https://doi.org/10.1093/cid/cit417

Cite

Register to see more suggestions